S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:EPIX

ESSA Pharma (EPIX) Stock Price, News & Analysis

$8.49
-0.07 (-0.82%)
(As of 03/28/2024 ET)
Today's Range
$8.22
$8.70
50-Day Range
$6.80
$10.65
52-Week Range
$2.56
$11.67
Volume
119,399 shs
Average Volume
159,725 shs
Market Capitalization
$375.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.50

ESSA Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
94.3% Upside
$16.50 Price Target
Short Interest
Healthy
4.56% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.43mentions of ESSA Pharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$27,700 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.80) to ($1.13) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.05 out of 5 stars

Medical Sector

347th out of 938 stocks

Pharmaceutical Preparations Industry

152nd out of 426 stocks

EPIX stock logo

About ESSA Pharma Stock (NASDAQ:EPIX)

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

EPIX Stock Price History

EPIX Stock News Headlines

EPIX Jul 2024 7.500 call
EPIX Jul 2024 12.500 put
Did you make $29,000 two days with AI options trades?
What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:
ESSA Pharma: Q1 Earnings Insights
Did you make $29,000 two days with AI options trades?
What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:
Recap: ESSA Pharma Q4 Earnings
See More Headlines
Receive EPIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ESSA Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/13/2024
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:EPIX
Employees
50
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.50
High Stock Price Target
$17.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+94.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-26,580,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.30 per share

Miscellaneous

Free Float
37,735,000
Market Cap
$375.60 million
Optionable
Optionable
Beta
1.64
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. David Ross Parkinson M.D. (Age 74)
    President, CEO & Director
    Comp: $814.15k
  • Mr. David S. Wood C.M.A. (Age 67)
    CPA, CMA, CPA, M.B.A., MBA, Chief Financial Officer
    Comp: $590.39k
  • Mr. Peter A. Virsik M.B.A. (Age 53)
    M.S., Executive VP & COO
    Comp: $645.95k
  • Dr. Alessandra Cesano M.D. (Age 63)
    Ph.D., Chief Medical Officer & Executive VP
    Comp: $623.93k
  • Chandtip Chandhasin
    Executive
  • Erica Osbourne
    Executive
  • Erin Rudsinski
    Executive
  • Loleta Harris
    Executive
  • Neil Thapar
    Executive
  • Nkengyal Barber
    Executive

EPIX Stock Analysis - Frequently Asked Questions

Should I buy or sell ESSA Pharma stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ESSA Pharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EPIX shares.
View EPIX analyst ratings
or view top-rated stocks.

What is ESSA Pharma's stock price target for 2024?

2 Wall Street analysts have issued 12 month price targets for ESSA Pharma's stock. Their EPIX share price targets range from $16.00 to $17.00. On average, they anticipate the company's share price to reach $16.50 in the next twelve months. This suggests a possible upside of 94.3% from the stock's current price.
View analysts price targets for EPIX
or view top-rated stocks among Wall Street analysts.

How have EPIX shares performed in 2024?

ESSA Pharma's stock was trading at $6.60 at the beginning of 2024. Since then, EPIX shares have increased by 28.6% and is now trading at $8.49.
View the best growth stocks for 2024 here
.

Are investors shorting ESSA Pharma?

ESSA Pharma saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 928,600 shares, a drop of 5.2% from the February 29th total of 979,400 shares. Based on an average daily trading volume, of 152,800 shares, the days-to-cover ratio is currently 6.1 days. Currently, 4.6% of the company's shares are short sold.
View ESSA Pharma's Short Interest
.

When is ESSA Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our EPIX earnings forecast
.

How were ESSA Pharma's earnings last quarter?

ESSA Pharma Inc. (NASDAQ:EPIX) announced its quarterly earnings results on Tuesday, February, 13th. The company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.03.

What other stocks do shareholders of ESSA Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ESSA Pharma investors own include RedHill Biopharma (RDHL), Aurinia Pharmaceuticals (AUPH), Lipocine (LPCN), Trevena (TRVN), Allena Pharmaceuticals (ALNA), Agile Therapeutics (AGRX), Biopharmx (BPMX), Corbus Pharmaceuticals (CRBP) and Heat Biologics (HTBX).

Who are ESSA Pharma's major shareholders?

ESSA Pharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include PFM Health Sciences LP (7.39%), RTW Investments LP (5.21%), BNP Paribas Financial Markets (0.13%), Royal Bank of Canada (0.07%), Citadel Advisors LLC (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include David Ross Parkinson, Franklin M Berger, Growth N V Biotech and Peter Virsik.
View institutional ownership trends
.

How do I buy shares of ESSA Pharma?

Shares of EPIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EPIX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners